Medicare Rates For Drug Eluting Stents Unchanged In Fiscal 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Hospital inpatient prospective payment system final rule retains current Medicare payments. Boston Scientific, Johnson & Johnson/Cordis offered separate proposals to reflect higher cost of “complex,” multi-vessel stenting procedures, but CMS will wait an additional year for more MedPAR data before restructuring the DRGs.